Complete ablation of tumors using synchronous chemoradiation with bimetallic theranostic nanoparticles

Nosrati, Hamed; Attari, Elahe; Abhari, Fatemeh; Barsbay, Murat; Ghaffarlou, Mohammadreza; Mousazadeh, Navid; Vaezi, Rasoul; Kavetskyy, Taras; Rezaeejam, Hamed; Webster, Thomas J.; Johari, Behrooz; Danafar, Hossein

doi:10.1016/j.bioactmat.2021.05.015

Cited by 47 publications

(25 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The high-resolution Gd 4d XPS spectrum of Gd 2 O 3 @BSA-Au shows Gd 4d 5/2 and Gd 4d 3/2 spin–orbit peaks at the binding energies of 141.7 and 148.01 eV, respectively (Figure S2b). In the 4f high-resolution spectrum of gold, there are two peaks that correspond to the 4f 7/2 and 4f 5/2 of Au (0), respectively, with binding energies of 84.3 and 87.9 eV (Figure f). , The presence of C 1s peaks confirms the existence of BSA in the structure of Gd 2 O 3 @BSA and Gd 2 O 3 @BSA-Au NPs (Figure S2a,c).…”

Section: Resultsmentioning

confidence: 74%

Enhanced In Vivo Radiotherapy of Breast Cancer Using Gadolinium Oxide and Gold Hybrid Nanoparticles

Nosrati

Salehiabar

Charmi

et al. 2023

ACS Appl. Bio Mater.

Self Cite

View full text Add to dashboard Cite

Radiation therapy has demonstrated promising effectiveness against several types of cancers. X-ray radiation therapy can be made further effective by utilizing nanoparticles of high-atomic-number (high-Z) materials that act as radiosensitizers. Here, in purpose of maximizing the radiation therapy within tumors, bovine serum albumin capped gadolinium oxide and gold nanoparticles (Gd 2 O 3 @BSA-Au NPs) are developed as a bimetallic radiosensitizer. In this study, we incorporate two high-Z-based nanoparticles, Au and Gd, in a single nanoplatform. The radiosensitizing ability of the nanoparticles was assessed with a series of in vitro tests, following evaluation in vivo in a breast cancer murine model. Enhanced tumor suppression is observed in the group that received radiation after administration of Gd 2 O 3 @BSA-Au NPs. As a result, cancer therapy efficacy is significantly improved by applying Gd 2 O 3 @BSA-Au NPs under X-ray irradiation, as evidenced by studies evaluating cell viability, proliferation, reactive oxygen species production, and in vivo anti-tumor effect.

show abstract

Section: Resultsmentioning

confidence: 74%

Enhanced In Vivo Radiotherapy of Breast Cancer Using Gadolinium Oxide and Gold Hybrid Nanoparticles

Nosrati

Salehiabar

Charmi

et al. 2023

ACS Appl. Bio Mater.

Self Cite

View full text Add to dashboard Cite

show abstract

“…The Fe 3 O 4 nanoparticles (IONPs) do not display a characteristic peak, whereas discernible absorption is observed in the spectrum of Bi 2 S 3 @BSA nanoparticles at 265 nm, which indicates the coating of BSA. [ 36 ] The same peak appeared at a higher wavelength for Bi 2 S 3 @BSA‐Fe 3 O 4 , indicating the interaction of Fe 3 O 4 with Bi 2 S 3 @BSA in the final structure. CUR shows a broad peak at 428 nm.…”

Section: Resultsmentioning

confidence: 90%

Preparation and evaluation of bismuth sulfide and magnetite‐based theranostic nanohybrid as drug carrier and dual MRI/CT contrast agent

Nosrati

Salehiabar

Mozafari

et al. 2022

Applied Organom Chemis

Self Cite

View full text Add to dashboard Cite

Due to the increased incidence and population growth that has been leading to growing number of cases worldwide, early diagnosis and treatment of cancer is crucial. Low density cancer tissue cannot be diagnosed before progressing toward a metastatic stage. Thus, theranostic systems play a significant role in assisting timely diagnosis and treatment. The combination of magnetic resonance imaging (MRI) and computed tomography (CT) contrast agents in a single probe is of high importance and necessity, where individual strengths of each approach can be merged while shortcomings of each modality could be compensated. With this motivation, we have developed and synthesized Bi2S3@BSA‐Fe3O4 nanoparticles as a dual MRI/CT contrast agent and carrier of curcumin (CUR) as natural anticancer drug. The nanoparticles shortened both the longitudinal (T1) and transverse (T2), MRI relaxation times, with a more distinct effect on producing negative contrast (T2) images with a relaxivity (r2) of 54.73 mM−1 s−1. The magnetite/bismuth hybrid nanoparticle also was capable of increasing CT image contrast. Further, in vitro cytotoxicity assay showed high biocompatibility of the synthesized nanoparticles. Furthermore, in vitro cytotoxicity assay on cancer cells showed high anticancer activity of the synthesized nanoparticles.

show abstract

“…Therapeutic nanocarriers exhibit different therapeutic effects in different diseases, synergistically enter the tumour with chemotherapeutic drugs in vivo, and exhibit excellent CT imaging capabilities. 46 , 47 The X-ray attenuation property of CTPA@DOX was first examined in vitro to evaluate the potential of CTPA@DOX for CT imaging. It was observed that the higher the AuNP concentration, the more prominent the brightness of CT imaging ( Figure 6A ).…”

Section: Resultsmentioning

confidence: 99%

Gold Nanoparticle-Incorporated Chitosan Nanogels as a Theranostic Nanoplatform for CT Imaging and Tumour Chemotherapy

Liu¹,

Zhou²,

Xuan³

et al. 2022

IJN

View full text Add to dashboard Cite

Purpose The translation of nanocarrier-based theranostics into cancer treatment is limited by their poor cellular uptake, low drug-loading capacity, uncontrolled drug release, and insufficient imaging ability. Methods In this study, novel hybrid nanogels were fabricated as theranostic nanocarriers by modifying chitosan (CTS)/tripolyphosphate (TPP) nanoparticles (NPs) with polyacrylic acid (PAA) and further conjugating cysteine-functionalized gold nanoparticles (AuNPs). Results The resultant nanogels, referred to as CTS/TPP/PAA@AuNPs (CTPA), exhibited excellent colloidal stability and a high encapsulation rate of 87% for the cationic drug doxorubicin (DOX). In the tumour microenvironment, the acidic pH and overexpression of lysozyme triggered CTPA@DOX to degrade and emit smaller nanoblocks (30–40 nm), which sequentially released the drug in a tumour-responsive manner. Cellular uptake experiments demonstrated that CTPA facilitates the entry of DOX into the cytoplasm. Furthermore, as visualised through AuNP-mediated computed tomography (CT) imaging, CTPA@DOX enabled favourable accumulation in the tumour. Our in vitro and in vivo data demonstrated that CTPA enabled advanced tumour cell-targeting delivery of DOX, which showed greater anti-tumour activity and biosafety than free DOX. Conclusion The natural polymer CTS was developed for degradable nanogels, which can precisely track drugs with high antitumour activity. Additionally, the surface adjustment strategy can be assembled to achieve cationic drug loading and high drug-loading capacity, controlled drug release, and sufficient imaging ability. Therefore, multifunctional CTPA enables efficient drug delivery and CT imaging, which is expected to provide a valuable strategy for designing advanced theranostic systems.

show abstract

Complete ablation of tumors using synchronous chemoradiation with bimetallic theranostic nanoparticles

Cited by 47 publications

References 43 publications

Enhanced In Vivo Radiotherapy of Breast Cancer Using Gadolinium Oxide and Gold Hybrid Nanoparticles

Enhanced In Vivo Radiotherapy of Breast Cancer Using Gadolinium Oxide and Gold Hybrid Nanoparticles

Preparation and evaluation of bismuth sulfide and magnetite‐based theranostic nanohybrid as drug carrier and dual MRI/CT contrast agent

Gold Nanoparticle-Incorporated Chitosan Nanogels as a Theranostic Nanoplatform for CT Imaging and Tumour Chemotherapy

Contact Info

Product

Resources

About